SEP 16, 2015 5:00 AM PDT

Synthetic Chemists to Aid the Community for Open Antimicrobial Drug Discovery

Speakers
  • Program Coordinator: Community for Open Antimicrobial Drug Discovery, University of Queensland
    Biography
      Dr. Mark Blaskovich is Program Coordinator: Hit Validation & Chemistry for the Community for Open Antimicrobial Drug Discovery, and a Senior Research Officer at the Institute for Molecular Bioscience at The University of Queensland. He has extensive medicinal chemistry expertise and over 15 years of industrial drug development experience, most recently as Chief Operating Officer at Mimetica (Australia), where he managed the drug discovery and development program for melanocortin-5 receptor antagonists leading to a compound currently in Phase II human trials for treatment of acne. In his previous role at CEPTYR (Seattle) he led a multidisciplinary team that developed a preclinical candidate for protein tyrosine phosphatase 1B, while at Molecumetics (Seattle) he headed a $2m/yr industrial collaboration on peptidomimetic compounds targeting proteases and GPCRs. Since starting at The University of Queensland, Mark has been working on developing new antibiotics to treat drug resistant pathogens. He has published over thirty articles, is an inventor on eight patent families with over 100 granted and pending applications, and is author of 'The Handbook on Syntheses of Amino Acids'.

    Abstract:
    The antibiotic pipeline is broken, with a dearth of new antibiotics, a collapse in pharmaceutical company research1, and the exhaustion of chemical diversity contained in pharma libraries. "The low hanging fruit from the antibiotic tree has probably already been picked and new sources of compounds are needed."2 We believe that there is an untapped resource contained in the laboratories of synthetic organic chemists; synthetic compounds prepared for other projects that have never been tested for their antimicrobial potential. These compounds, which are sitting at the back of benches and freezers, may have been synthesised to validate new synthetic routes, develop new methodologies, or create unusual structures. A global screening initiative will uncover this significant and rich chemical diversity held outside of corporate screening collections by providing a low-barrier access to testing. Antibacterial drugs occupy a unique property space that is vastly different to drugs developed for other therapeutic areas, suggesting that commercially available chemical compounds lack the physicochemical properties ideal for activity against bacteria and therefore, a varied source of chemical diversity needs to be investigated. We have created a Wellcome Trust-supported not-for-profit Open-Access initiative, The Community for Open Antimicrobial Drug Discovery [CO-ADD], to provide unencumbered free antimicrobial screening for any interested researcher.3 CO-ADD builds upon a suite of established in vitro and in vivo assays, medicinal chemistry and core researcher expertise and aims to unearth fresh chemical diversity for the treatment of bacterial infection.

    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    Loading Comments...
    Show Resources